Scientific Exhibit to Showcase Posters on Ganaxolone on Sunday, December 6th
RADNOR, Pa., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today that two abstracts featuring Marinus’s CNS-selective GABAA modulator, ganaxolone have been selected for poster presentation at the 69th Annual Meeting of the American Epilepsy Society, which will be held December 4-8, 2015, at the Pennsylvania Convention Center in Philadelphia, PA.
The posters, which will be presented on Sunday, December 6th, in Hall A of the Convention Center, include:
Title: Additional responder analysis on a phase 2 study of ganaxolone in patients with partial onset seizures
Poster Session #: 2.260
Presenting Author: Albena Patroneva, M.D.
Title: Clinical development of an intravenous formulation of ganaxolone for acute care patients supported by non-clinical toxicity studies conducted in rats and rabbits
Poster Session #: 2.238
Presenting Author: Julia Tsai, Ph.D.
Also on Sunday, December 6th, from 2:00 – 5:00 pm in Room 201A, Marinus will be hosting a scientific exhibit, featuring several scientific posters on ganaxolone, including new preclinical data for the recently developed intravenous (IV) formulation.
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety and convenient dosing, to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a CNS-selective GABAA modulator that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone IV is planned to enter clinical trials in 2016 and is being developed to treat status epilepticus. Ganaxolone IV is complemented by its oral dose forms, providing the potential for IV-to-oral continuation therapy for patients transitioning from acute care to outpatient settings.
Ganaxolone capsule is being evaluated in a Phase 3 multi-national clinical trial as adjunctive treatment of focal onset seizures in adults. Ganaxolone capsule and liquid are being studied in orphan pediatric indications with comorbidities in seizures and behavior disorders – PCDH19 epilepsy and Fragile X Syndrome. For more information visit www.marinuspharma.com.
RADNOR, Pa., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today that two abstracts featuring Marinus’s CNS-selective GABAA modulator, ganaxolone have been selected for poster presentation at the 69th Annual Meeting of the American Epilepsy Society, which will be held December 4-8, 2015, at the Pennsylvania Convention Center in Philadelphia, PA.
The posters, which will be presented on Sunday, December 6th, in Hall A of the Convention Center, include:
Title: Additional responder analysis on a phase 2 study of ganaxolone in patients with partial onset seizures
Poster Session #: 2.260
Presenting Author: Albena Patroneva, M.D.
Title: Clinical development of an intravenous formulation of ganaxolone for acute care patients supported by non-clinical toxicity studies conducted in rats and rabbits
Poster Session #: 2.238
Presenting Author: Julia Tsai, Ph.D.
Also on Sunday, December 6th, from 2:00 – 5:00 pm in Room 201A, Marinus will be hosting a scientific exhibit, featuring several scientific posters on ganaxolone, including new preclinical data for the recently developed intravenous (IV) formulation.
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety and convenient dosing, to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a CNS-selective GABAA modulator that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone IV is planned to enter clinical trials in 2016 and is being developed to treat status epilepticus. Ganaxolone IV is complemented by its oral dose forms, providing the potential for IV-to-oral continuation therapy for patients transitioning from acute care to outpatient settings.
Ganaxolone capsule is being evaluated in a Phase 3 multi-national clinical trial as adjunctive treatment of focal onset seizures in adults. Ganaxolone capsule and liquid are being studied in orphan pediatric indications with comorbidities in seizures and behavior disorders – PCDH19 epilepsy and Fragile X Syndrome. For more information visit www.marinuspharma.com.
